Publications - Page 41 sur 43 - RespiFIL - Filière de santé des maladies respiratoires rares

Voici les publications scientifiques relatives aux maladies respiratoires rares auxquelles les membres de la filière ont contribué, classées par groupes de pathologies (depuis juillet 2021).

Pneumopathies interstitielles diffuses (PID) 02/08/23
Extracellular Heat Shock Proteins as Therapeutic Targets and Biomarkers in Fibrosing Interstitial Lung Diseases

Tanguy J, Pommerolle L, Garrido C, Kolb M, Bonniaud P, Goirand F, Bellaye PS.

Int J Mol Sci. 2021 Aug 27;22(17):9316. Doi: 10.3390/ijms22179316.
Pneumopathies interstitielles diffuses (PID) 02/08/23
Disease Behaviour During the Peri-Diagnostic Period in Patients with Suspected Interstitial Lung Disease: The STARLINER Study

Wijsenbeek MS, Bendstrup E, Valenzuela C, Henry MT, Moor CC, Jouneau S, Fois AG, Moran-Mendoza O, Anees S, Mirt M, Bengus M, Gilberg F, Kirchgaessler KU, Vancheri C.

Adv Ther. 2021 Jul;38(7):4040-4056. Doi: 10.1007/s12325-021-01790-y.
Pneumopathies interstitielles diffuses (PID) 02/08/23
Patient-reported outcomes and patient-reported outcome measures in interstitial lung disease: where to go from here?

Kalluri M, Luppi F, Vancheri A, Vancheri C, Balestro E, Varone F, Mogulkoc N, Cacopardo G, Bargagli E, Renzoni E, Torrisi S, Calvello M, Libra A, Pavone M, Bonella F, Cottin V, Valenzuela C, Wijsenbeek M, Bendstrup E; 3rd International Summit for ILD (ISILD), Erice collaborators listed below.

Eur Respir Rev. 2021 May 25;30(160):210026. Doi: 10.1183/16000617.0026-2021.
Pneumopathies interstitielles diffuses (PID) 02/08/23
Care Delivery Models and Interstitial Lung Disease: The Role of the Specialized Center

Fisher JH, Cottin V.

Clin Chest Med. 2021 Jun;42(2):347-355. Doi: 10.1016/j.ccm.2021.03.013.
Pneumopathies interstitielles diffuses (PID) 02/08/23
Impact of lung morphology on clinical outcomes with riociguat in patients with pulmonary hypertension and idiopathic interstitial pneumonia: A post hoc subgroup analysis of the RISE-IIP study

Nathan SD, Cottin V, Behr J, Hoeper MM, Martinez FJ, Corte TJ, Keogh AM, Leuchte H, Mogulkoc N, Ulrich S, Wuyts WA, Yao Z, Ley-Zaporozhan J, Müller-Lisse UG, Scholle FD, Brüggenwerth G, Busse D, Nikkho S, Wells AU.

J Heart Lung Transplant. 2021 Jun;40(6):494-503. Doi: 10.1016/j.healun.2021.02.006.
Pneumopathies interstitielles diffuses (PID) 02/08/23
Estimates of epidemiology, mortality and disease burden associated with progressive fibrosing interstitial lung disease in France (the PROGRESS study)

Nasser M, Larrieu S, Boussel L, Si-Mohamed S, Bazin F, Marque S, Massol J, Thivolet-Bejui F, Chalabreysse L, Maucort-Boulch D, Hachulla E, Jouneau S, Le Lay K, Cottin V.

Respir Res. 2021 May 24;22(1):162. Doi: 10.1186/s12931-021-01749-1.
Pneumopathies interstitielles diffuses (PID) 02/08/23
Methylprednisolone pulse treatment improves ProSP-C trafficking in twins with SFTPC mutation: An isoform story?

Delestrain C, Aissat A, Simon S, Tarze A, Duprat E, Nattes E, Costes B, Delattre V, Finet S, Fanen P, Epaud R.

Br J Clin Pharmacol. 2021 May;87(5):2361-2373. Doi: 10.1111/bcp.14645.
Pneumopathies interstitielles diffuses (PID) 02/08/23
Impact of the COVID-19 lockdown on patients suffering from idiopathic interstitial pneumonia.

Beltramo G, Cransac A, Favrolt N, Spanjaard M, Zeller M, Cottin Y, Boulin M, Bonniaud P.

Respir Med Res. 2021 May;79:100808. Doi: 10.1016/j.resmer.2020.100808.
Pneumopathies interstitielles diffuses (PID) 02/08/23
Sleep in children and young adults with interstitial and diffuse lung disease.

Abdel-Latif Thomasson D, Abou Taam R, Berteloot L, Khirani S, Griffon L, Hadchouel A, Delacourt C, Fauroux B.

Sleep Med. 2021 Apr;80:23-29. Doi: 10.1016/j.sleep.2021.01.020.
Pneumopathies interstitielles diffuses (PID) 02/08/23
Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases

Cottin V, Richeldi L, Rosas I, Otaola M, Song JW, Tomassetti S, Wijsenbeek M, Schmitz M, Coeck C, Stowasser S, Schlenker-Herceg R, Kolb M; INBUILD Trial Investigators.

Respir Res. 2021 Mar 16;22(1):84. doi: 10.1186/s12931-021-01668-1.

FILTRER :

Par mot clé

Par maladies

Réinitialiser les filtres

Extracellular Heat Shock Proteins as Therapeutic Targets and Biomarkers in Fibrosing Interstitial Lung Diseases

Disease Behaviour During the Peri-Diagnostic Period in Patients with Suspected Interstitial Lung Disease: The STARLINER Study

Patient-reported outcomes and patient-reported outcome measures in interstitial lung disease: where to go from here?

Care Delivery Models and Interstitial Lung Disease: The Role of the Specialized Center

Impact of lung morphology on clinical outcomes with riociguat in patients with pulmonary hypertension and idiopathic interstitial pneumonia: A post hoc subgroup analysis of the RISE-IIP study

Estimates of epidemiology, mortality and disease burden associated with progressive fibrosing interstitial lung disease in France (the PROGRESS study)

Methylprednisolone pulse treatment improves ProSP-C trafficking in twins with SFTPC mutation: An isoform story?

Impact of the COVID-19 lockdown on patients suffering from idiopathic interstitial pneumonia.

Sleep in children and young adults with interstitial and diffuse lung disease.

Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases